Liminal BioSciences Expands R&D Pipeline With Novel Preclinical Program For Eosinophilic-Related Diseases

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases through tissue repair and resolution of inflammation ("Fairhaven R&D Program"). "This acquisition is a continuation and expansion of our strategy to build a diverse portfolio of early-stage R&D programs that complement our established research focus and our lead development opportunities with Ryplazim® and fezagepras," stated Kenneth Galbraith, Chief Executive Officer of Liminal BioSciences. "We are making progress on our selective GPR84 antagonist R&D program and we look forward to advancing the promising Fairhaven R&D Program in our laboratories at Liminal BioSciences, utilizing our extensive GPCR experience and supported by funding provided initially by certain Fairhaven shareholders." The Fairhaven R&D Program is based on the research of Dr. William Powell, Professor Emeritus in the Department of Medicine at McGill University, working in collaboration with Dr. Joshua Rokach of the Florida Institute of Technology (FIT). Drs. Powell and Rokach developed a series of potentially first-in-class, oral, selective OXE receptor antagonists against 5-oxo-ETE, one of the most potent human eosinophil chemoattractants. Migration of eosinophils to body sites including the lungs and intestines is mediated by eosinophil chemoattractants such as 5-oxo-ETE. Eosinophils play a key role in Type 2 inflammation-driven diseases, including certain respiratory and gastro-intestinal diseases. Dr. Powell will serve as an advisor to Liminal BioSciences on the Fairhaven R&D Program.